Landscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patients

Se Hoon Lee, Boram Lee, Joon Ho Shim, Kwang Woo Lee, Jae Won Yun, Sook Young Kim, Tae You Kim, Yeul Hong Kim, Young Hyeh Ko, Hyun Cheol Chung, Chang Sik Yu, Jeeyun Lee, Sun Young Rha, Tae Won Kim, Kyung Hae Jung, Seock Ah Im, Hyeong Gon Moon, Sukki Cho, Jin Hyoung Kang, Jihun Kim & 10 others Sang Kyum Kim, Han Suk Ryu, Sang Yun Ha, Jong Il Kim, Yeun Jun Chung, Cheolmin Kim, Hyung Lae Kim, Woong Yang Park, Dong Young Noh, Keunchil Park

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: With the emergence of next-generation sequencing (NGS) technology, profiling a wide range of genomic alterations has become a possibility resulting in improved implementation of targeted cancer therapy. In Asian populations, the prevalence and spectrum of clinically actionable genetic alterations has not yet been determined because of a lack of studies examining high-throughput cancer genomic data. Materials and Methods: To address this issue, 1,071 tumor samples were collected from five major cancer institutes in Korea and analyzed using targeted NGS at a centralized laboratory. Samples were either fresh frozen or formalin-fixed, paraffin embedded (FFPE) and the quality and yield of extracted genomic DNA was assessed. In order to estimate the effect of sample condition on the quality of sequencing results, tissue preparation method, specimen type (resected or biopsied) and tissue storage time were compared. Results: We detected 7,360 non-synonymous point mutations, 1,164 small insertions and deletions, 3,173 copy number alterations, and 462 structural variants. Fifty-four percent of tumors had one or more clinically relevant genetic mutation. The distribution of actionable variants was variable among different genes. Fresh frozen tissues, surgically resected specimens, and recently obtained specimens generated superior sequencing results over FFPE tissues, biopsied specimens, and tissues with long storage duration. Conclusion: In order to overcome, challenges involved in bringing NGS testing into routine clinical use, a centralized laboratory model was designed that could improve the NGS workflows, provide appropriate turnaround times and control costs with goal of enabling precision medicine.

Original languageEnglish
Pages (from-to)211-222
Number of pages12
JournalCancer Research and Treatment
Volume51
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Neoplasms
Paraffin
Formaldehyde
Precision Medicine
Workflow
Cost Control
Korea
Point Mutation
Technology
Mutation
DNA
Population
Genes
Therapeutics

Keywords

  • Actionable genetic alteration
  • Cancer genomics
  • Next generation sequencing
  • Precision medicine
  • Targeted panel sequencing

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Landscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patients. / Lee, Se Hoon; Lee, Boram; Shim, Joon Ho; Lee, Kwang Woo; Yun, Jae Won; Kim, Sook Young; Kim, Tae You; Kim, Yeul Hong; Ko, Young Hyeh; Chung, Hyun Cheol; Yu, Chang Sik; Lee, Jeeyun; Rha, Sun Young; Kim, Tae Won; Jung, Kyung Hae; Im, Seock Ah; Moon, Hyeong Gon; Cho, Sukki; Kang, Jin Hyoung; Kim, Jihun; Kim, Sang Kyum; Ryu, Han Suk; Ha, Sang Yun; Kim, Jong Il; Chung, Yeun Jun; Kim, Cheolmin; Kim, Hyung Lae; Park, Woong Yang; Noh, Dong Young; Park, Keunchil.

In: Cancer Research and Treatment, Vol. 51, No. 1, 01.01.2019, p. 211-222.

Research output: Contribution to journalArticle

Lee, SH, Lee, B, Shim, JH, Lee, KW, Yun, JW, Kim, SY, Kim, TY, Kim, YH, Ko, YH, Chung, HC, Yu, CS, Lee, J, Rha, SY, Kim, TW, Jung, KH, Im, SA, Moon, HG, Cho, S, Kang, JH, Kim, J, Kim, SK, Ryu, HS, Ha, SY, Kim, JI, Chung, YJ, Kim, C, Kim, HL, Park, WY, Noh, DY & Park, K 2019, 'Landscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patients', Cancer Research and Treatment, vol. 51, no. 1, pp. 211-222. https://doi.org/10.4143/crt.2018.132
Lee, Se Hoon ; Lee, Boram ; Shim, Joon Ho ; Lee, Kwang Woo ; Yun, Jae Won ; Kim, Sook Young ; Kim, Tae You ; Kim, Yeul Hong ; Ko, Young Hyeh ; Chung, Hyun Cheol ; Yu, Chang Sik ; Lee, Jeeyun ; Rha, Sun Young ; Kim, Tae Won ; Jung, Kyung Hae ; Im, Seock Ah ; Moon, Hyeong Gon ; Cho, Sukki ; Kang, Jin Hyoung ; Kim, Jihun ; Kim, Sang Kyum ; Ryu, Han Suk ; Ha, Sang Yun ; Kim, Jong Il ; Chung, Yeun Jun ; Kim, Cheolmin ; Kim, Hyung Lae ; Park, Woong Yang ; Noh, Dong Young ; Park, Keunchil. / Landscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patients. In: Cancer Research and Treatment. 2019 ; Vol. 51, No. 1. pp. 211-222.
@article{8ccbb4be37524e21a1664e72c8493d74,
title = "Landscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patients",
abstract = "Purpose: With the emergence of next-generation sequencing (NGS) technology, profiling a wide range of genomic alterations has become a possibility resulting in improved implementation of targeted cancer therapy. In Asian populations, the prevalence and spectrum of clinically actionable genetic alterations has not yet been determined because of a lack of studies examining high-throughput cancer genomic data. Materials and Methods: To address this issue, 1,071 tumor samples were collected from five major cancer institutes in Korea and analyzed using targeted NGS at a centralized laboratory. Samples were either fresh frozen or formalin-fixed, paraffin embedded (FFPE) and the quality and yield of extracted genomic DNA was assessed. In order to estimate the effect of sample condition on the quality of sequencing results, tissue preparation method, specimen type (resected or biopsied) and tissue storage time were compared. Results: We detected 7,360 non-synonymous point mutations, 1,164 small insertions and deletions, 3,173 copy number alterations, and 462 structural variants. Fifty-four percent of tumors had one or more clinically relevant genetic mutation. The distribution of actionable variants was variable among different genes. Fresh frozen tissues, surgically resected specimens, and recently obtained specimens generated superior sequencing results over FFPE tissues, biopsied specimens, and tissues with long storage duration. Conclusion: In order to overcome, challenges involved in bringing NGS testing into routine clinical use, a centralized laboratory model was designed that could improve the NGS workflows, provide appropriate turnaround times and control costs with goal of enabling precision medicine.",
keywords = "Actionable genetic alteration, Cancer genomics, Next generation sequencing, Precision medicine, Targeted panel sequencing",
author = "Lee, {Se Hoon} and Boram Lee and Shim, {Joon Ho} and Lee, {Kwang Woo} and Yun, {Jae Won} and Kim, {Sook Young} and Kim, {Tae You} and Kim, {Yeul Hong} and Ko, {Young Hyeh} and Chung, {Hyun Cheol} and Yu, {Chang Sik} and Jeeyun Lee and Rha, {Sun Young} and Kim, {Tae Won} and Jung, {Kyung Hae} and Im, {Seock Ah} and Moon, {Hyeong Gon} and Sukki Cho and Kang, {Jin Hyoung} and Jihun Kim and Kim, {Sang Kyum} and Ryu, {Han Suk} and Ha, {Sang Yun} and Kim, {Jong Il} and Chung, {Yeun Jun} and Cheolmin Kim and Kim, {Hyung Lae} and Park, {Woong Yang} and Noh, {Dong Young} and Keunchil Park",
year = "2019",
month = "1",
day = "1",
doi = "10.4143/crt.2018.132",
language = "English",
volume = "51",
pages = "211--222",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Society for Thoracic and Cardiovascular Surgery",
number = "1",

}

TY - JOUR

T1 - Landscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patients

AU - Lee, Se Hoon

AU - Lee, Boram

AU - Shim, Joon Ho

AU - Lee, Kwang Woo

AU - Yun, Jae Won

AU - Kim, Sook Young

AU - Kim, Tae You

AU - Kim, Yeul Hong

AU - Ko, Young Hyeh

AU - Chung, Hyun Cheol

AU - Yu, Chang Sik

AU - Lee, Jeeyun

AU - Rha, Sun Young

AU - Kim, Tae Won

AU - Jung, Kyung Hae

AU - Im, Seock Ah

AU - Moon, Hyeong Gon

AU - Cho, Sukki

AU - Kang, Jin Hyoung

AU - Kim, Jihun

AU - Kim, Sang Kyum

AU - Ryu, Han Suk

AU - Ha, Sang Yun

AU - Kim, Jong Il

AU - Chung, Yeun Jun

AU - Kim, Cheolmin

AU - Kim, Hyung Lae

AU - Park, Woong Yang

AU - Noh, Dong Young

AU - Park, Keunchil

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: With the emergence of next-generation sequencing (NGS) technology, profiling a wide range of genomic alterations has become a possibility resulting in improved implementation of targeted cancer therapy. In Asian populations, the prevalence and spectrum of clinically actionable genetic alterations has not yet been determined because of a lack of studies examining high-throughput cancer genomic data. Materials and Methods: To address this issue, 1,071 tumor samples were collected from five major cancer institutes in Korea and analyzed using targeted NGS at a centralized laboratory. Samples were either fresh frozen or formalin-fixed, paraffin embedded (FFPE) and the quality and yield of extracted genomic DNA was assessed. In order to estimate the effect of sample condition on the quality of sequencing results, tissue preparation method, specimen type (resected or biopsied) and tissue storage time were compared. Results: We detected 7,360 non-synonymous point mutations, 1,164 small insertions and deletions, 3,173 copy number alterations, and 462 structural variants. Fifty-four percent of tumors had one or more clinically relevant genetic mutation. The distribution of actionable variants was variable among different genes. Fresh frozen tissues, surgically resected specimens, and recently obtained specimens generated superior sequencing results over FFPE tissues, biopsied specimens, and tissues with long storage duration. Conclusion: In order to overcome, challenges involved in bringing NGS testing into routine clinical use, a centralized laboratory model was designed that could improve the NGS workflows, provide appropriate turnaround times and control costs with goal of enabling precision medicine.

AB - Purpose: With the emergence of next-generation sequencing (NGS) technology, profiling a wide range of genomic alterations has become a possibility resulting in improved implementation of targeted cancer therapy. In Asian populations, the prevalence and spectrum of clinically actionable genetic alterations has not yet been determined because of a lack of studies examining high-throughput cancer genomic data. Materials and Methods: To address this issue, 1,071 tumor samples were collected from five major cancer institutes in Korea and analyzed using targeted NGS at a centralized laboratory. Samples were either fresh frozen or formalin-fixed, paraffin embedded (FFPE) and the quality and yield of extracted genomic DNA was assessed. In order to estimate the effect of sample condition on the quality of sequencing results, tissue preparation method, specimen type (resected or biopsied) and tissue storage time were compared. Results: We detected 7,360 non-synonymous point mutations, 1,164 small insertions and deletions, 3,173 copy number alterations, and 462 structural variants. Fifty-four percent of tumors had one or more clinically relevant genetic mutation. The distribution of actionable variants was variable among different genes. Fresh frozen tissues, surgically resected specimens, and recently obtained specimens generated superior sequencing results over FFPE tissues, biopsied specimens, and tissues with long storage duration. Conclusion: In order to overcome, challenges involved in bringing NGS testing into routine clinical use, a centralized laboratory model was designed that could improve the NGS workflows, provide appropriate turnaround times and control costs with goal of enabling precision medicine.

KW - Actionable genetic alteration

KW - Cancer genomics

KW - Next generation sequencing

KW - Precision medicine

KW - Targeted panel sequencing

UR - http://www.scopus.com/inward/record.url?scp=85059902507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059902507&partnerID=8YFLogxK

U2 - 10.4143/crt.2018.132

DO - 10.4143/crt.2018.132

M3 - Article

VL - 51

SP - 211

EP - 222

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 1

ER -